FDA should re­assess post­mar­ket tri­als for can­cer drugs ap­proved via ac­cel­er­at­ed path­way, re­searchers say

The FDA may need to re­assess how con­fir­ma­to­ry tri­als are con­duct­ed af­ter just one-fifth of such tri­als for can­cer drug in­di­ca­tions ap­proved via the FDA’s ac­cel­er­at­ed ap­proval path­way have demon­strat­ed im­prove­ments in over­all sur­vival (OS), re­searchers re­port­ed Tues­day in JA­MA In­ter­nal Med­i­cine re­search.

The re­searchers looked at 93 can­cer drug in­di­ca­tions grant­ed ac­cel­er­at­ed ap­proval by the FDA from 1992 through May 2017, find­ing con­fir­ma­to­ry tri­als re­port­ed that 20% had im­prove­ment in over­all sur­vival, 21% had im­prove­ment in a dif­fer­ent sur­ro­gate mea­sure and 20% had im­prove­ment in the same sur­ro­gate mea­sure used in con­fir­ma­to­ry tri­als and preap­proval tri­als.

“Ap­pro­pri­ate use of sur­ro­gates for ac­cel­er­at­ed ap­proval re­quires an ap­pre­ci­a­tion for how the va­lid­i­ty of a sur­ro­gate can vary from one in­di­ca­tion to an­oth­er. One strat­e­gy for cap­tur­ing this vari­abil­i­ty would be to have a con­tin­u­al­ly up­dat­ed data­base of strengths of sur­ro­gate val­i­da­tion across tu­mor types as re­sults from new­er tri­als be­come avail­able,” the re­searchers from the Pro­gram on Reg­u­la­tion, Ther­a­peu­tics, and Law (POR­TAL), Di­vi­sion of Phar­ma­coepi­demi­ol­o­gy and Phar­ma­coeco­nom­ics at Brigham and Women’s Hos­pi­tal and Har­vard Med­ical School said.

They al­so called to adapt the FDA’s re­cent­ly pub­lished list of sur­ro­gate mea­sures to in­clude the strengths of sur­ro­ga­cy val­i­da­tion. “Con­firm­ing the clin­i­cal ben­e­fit of a can­cer drug us­ing the same sur­ro­gate mea­sure as the one used in its preap­proval tri­al should be re­served for when the sur­ro­gate mea­sure for a giv­en in­di­ca­tion has been val­i­dat­ed,” they added.

In ad­di­tion, the re­searchers ad­dressed po­ten­tial crit­ics who may dis­agree that it is im­por­tant to demon­strate an OS ben­e­fit to ver­i­fy a clin­i­cal ben­e­fit. They use the ex­am­ple of ima­tinib for chron­ic myeloid leukemia (CML), which was ap­proved with­out the need to re­port OS ben­e­fit in tri­als.

“How­ev­er, ima­tinib for CML is an atyp­i­cal ex­am­ple of a drug with such huge ben­e­fits that it is con­sid­ered life­sav­ing rather than life pro­long­ing,” they wrote. “Most ap­proved can­cer drugs fall in­to the lat­ter cat­e­go­ry, and as a re­sult, even im­pres­sive ef­fects on sur­ro­gate mea­sures may not trans­late to ex­tend­ed sur­vival ben­e­fits. Thus, al­though im­prove­ment in sur­ro­gate mea­sures alone may be ac­cept­able for ac­cel­er­at­ed ap­proval, the con­fir­ma­to­ry tri­als should ver­i­fy the clin­i­cal ben­e­fit in terms of ben­e­fits in OS, qual­i­ty of life, or a valid sur­ro­gate of ei­ther.

“Re­assess­ment of the re­quire­ments for con­fir­ma­to­ry tri­als may be nec­es­sary to ob­tain more clin­i­cal­ly mean­ing­ful in­for­ma­tion,” they added. “FDA should adopt a con­sis­tent ap­proach re­gard­ing the re­sults of con­fir­ma­to­ry tri­als to help physi­cians and pa­tients bet­ter un­der­stand what con­sti­tutes ver­i­fi­ca­tion of ben­e­fit.”

Com­men­taries

In a com­men­tary ac­com­pa­ny­ing the study and a sec­ond study on can­cer drugs ap­proved based on re­sponse rates, pro­fes­sors from the Perel­man School of Med­i­cine at the Uni­ver­si­ty of Penn­syl­va­nia crit­i­cize the FDA for call­ing the ac­cel­er­at­ed ap­proval process a suc­cess be­cause on­ly 5% of con­fir­ma­to­ry tri­als failed.

“FDA is con­grat­u­lat­ing it­self, us­ing its own ‘sur­ro­gate’ end points, which it can al­ter to demon­strate that its poli­cies are suc­ceed­ing. This low rate of with­drawals is not a valid mea­sure of suc­cess. There is no good rea­son for the FDA to re­ly so heav­i­ly on ac­cel­er­at­ed ap­proval us­ing re­sponse rates or oth­er un­re­li­able sur­ro­gate end­points,” they write.

They al­so point to three nec­es­sary pol­i­cy changes: “First, the end­point for con­fir­ma­to­ry tri­als should nev­er be the same sur­ro­gate end­point used in the orig­i­nal study, and a new sur­ro­gate end­point should be used on­ly if there is a proven cor­re­la­tion be­tween that end­point and over­all sur­vival or im­proved qual­i­ty of life. Most con­fir­ma­to­ry tri­als should use over­all sur­vival and/or qual­i­ty-of-life end­points.

“Sec­ond, ap­proval of drugs should be rapid­ly with­drawn when con­fir­ma­to­ry tri­als re­port se­ri­ous tox­ic ef­fects or do not re­port mean­ing­ful clin­i­cal im­prove­ments. Fi­nal­ly, the con­fir­ma­to­ry tri­als must be con­duct­ed prompt­ly, with cred­i­ble threats of re­versed ap­proval. Hav­ing more than a quar­ter of tri­als in­com­plete years af­ter ac­cel­er­at­ed ap­proval is un­ac­cept­able,” they add.

An­oth­er com­men­tary from a pro­fes­sor at Yale School of Med­i­cine and a pro­fes­sor at the Uni­ver­si­ty of Birm­ing­ham in the UK ex­plain how the find­ings from the two stud­ies “build on a grow­ing body of work, which in ag­gre­gate, demon­strate a post­mar­ket­ing eval­u­a­tion process that is serv­ing nei­ther pa­tients nor so­ci­ety well.”

As­sess­ment of the Clin­i­cal Ben­e­fit of Can­cer Drugs Re­ceiv­ing Ac­cel­er­at­ed Ap­proval

An Overview of Can­cer Drugs Ap­proved by the US Food and Drug Ad­min­is­tra­tion Based on the Sur­ro­gate End Point of Re­sponse Rate

Ac­cel­er­at­ed Ap­proval of Can­cer Drugs—Right­ing the Ship of the US Food and Drug Ad­min­is­tra­tion

An In­ter­na­tion­al Per­spec­tive on Drugs for Can­cer


First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Im­age: Jacque­lyn Mar­tin AP

Da­ta Lit­er­a­cy: The Foun­da­tion for Mod­ern Tri­al Ex­e­cu­tion

In 2016, the International Council for Harmonisation (ICH) updated their “Guidelines for Good Clinical Practice.” One key shift was a mandate to implement a risk-based quality management system throughout all stages of a clinical trial, and to take a systematic, prioritized, risk-based approach to clinical trial monitoring—on-site monitoring, remote monitoring, or any combination thereof.

Pfiz­er's big block­buster Xel­janz flunks its post-mar­ket­ing safe­ty study, re­new­ing harsh ques­tions for JAK class

When the FDA approved Pfizer’s JAK inhibitor Xeljanz for rheumatoid arthritis in 2012, they slapped on a black box warning for a laundry list of adverse events and required the New York drugmaker to run a long-term safety study.

That study has since become a consistent headache for Pfizer and their blockbuster molecule. Last year, Pfizer dropped the entire high dose cohort after an independent monitoring board found more patients died in that group than in the low dose arm or a control arm of patients who received one of two TNF inhibitors, Enbrel or Humira.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: EU and As­traZeneca trade blows over slow­downs; Un­usu­al unions pop up to test an­ti­bod­ies, vac­cines

After coming under fire for manufacturing delays last week, AstraZeneca’s feud with the European Union has spilled into the open.

The bloc accused the pharma giant on Wednesday of pulling out of a meeting to discuss cuts to its vaccine supplies, the AP reported. AstraZeneca denied the reports, saying it still planned on attending the discussion.

Early Wednesday, an EU Commission spokeswoman said that “the representative of AstraZeneca had announced this morning, had informed us this morning that their participation is not confirmed, is not happening.” But an AstraZeneca spokesperson later called the reports “not accurate.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.

Adeno-associated virus-1 illustration; the use of AAVs resurrected the gene therapy field, but companies are now testing the limits of a 20-year-old technology (File photo, Shutterstock)

Af­ter 3 deaths rock the field, gene ther­a­py re­searchers con­tem­plate AAV's fu­ture

Nicole Paulk was scrolling through her phone in bed early one morning in June when an email from a colleague jolted her awake. It was an article: Two patients in an Audentes gene therapy trial had died, grinding the study to a halt.

Paulk, who runs a gene therapy lab at the University of California, San Francisco, had planned to spend the day listening to talks at the American Association for Cancer Research annual meeting, which was taking place that week. Instead, she skipped the conference, canceled every work call on her calendar and began phoning colleagues across academia and industry, trying to figure out what happened and why. All the while, a single name hung in the back of her head.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Pascal Soriot, AP

As­traZeneca CEO Pas­cal So­ri­ot sev­ers an un­usu­al board con­nec­tion, steer­ing clear of con­flicts while re­tain­ing im­por­tant al­liances

CSL Behring chief Paul Perreault scored an unusual coup last summer when he added AstraZeneca CEO Pascal Soriot to the board, via Zoom. It’s rare, to say the least, to see a Big Pharma CEO take any board post in an industry where interests can simultaneously connect and collide on multiple levels of operations.

The tie set the stage for an important manufacturing connection. The Australian pharma giant agreed to supply the country with 10s of millions of AstraZeneca’s Covid-19 vaccine, once it passes regulatory muster.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Re­call re­port: Nos­trum re­calls an­oth­er lot of met­formin as car­cino­gen con­cerns con­tin­ue

For the second time in January and the third time in the last two months, a Kansas City, MO laboratory has pulled a lot of generic metformin from the shelves after it was found to contain higher-than-allowed levels of a probable human carcinogen.

The FDA on Tuesday announced that Nostrum Laboratories was voluntarily recalling a lot of metformin HCl extended release tablets, USP 750 mg, a type 2 diabetes drug (the generic equivalent to Glucophage tablets) after testing discovered elevated levels of nitrosamine, the probable carcinogen.

Mer­ck scraps Covid-19 vac­cine pro­grams af­ter they fail to mea­sure up on ef­fi­ca­cy in an­oth­er ma­jor set­back in the glob­al fight

After turning up late to the vaccine development game in the global fight against Covid-19, Merck is now making a quick exit.

The pharma giant is reporting this morning that it’s decided to drop development of 2 vaccines — V590 and V591 — after taking a look at Phase I data that simply don’t measure up to either the natural immune response seen in people exposed to the virus or the vaccines already on or near the market.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,900+ biopharma pros reading Endpoints daily — and it's free.

Anthony Fauci, NIAID director (AP Images)

As new Covid-19 task force gets un­der­way, threat looms of vac­cine, mon­o­clon­al an­ti­body-re­sis­tant vari­ants

Hours before President Biden’s Covid-19 team gave their first virtual press conference, the famed AIDS researcher David Ho delivered concerning news in a new pre-print: SARS-CoV-2 B.1.351, the variant that emerged in South Africa, is “markedly more resistant” to antibodies from convalescent plasma and vaccinated individuals.

The news for several monoclonal antibodies, including Eli Lilly’s bamlanivimab, was even worse: Their ability to neutralize was “completely or markedly abolished,” Ho wrote. Lilly’s antibody cocktail, which was just shown to dramatically reduce the risk of hospitalizations or death, also became far less potent.

Florian Brand (L) and Srinivas Rao (ATAI)

Psy­che­del­ic biotech ATAI hopes to ex­pand port­fo­lio through re­search part­ner­ship with Mass Gen­er­al

Psychedelics have made a comeback for mental health research, with companies like startup biotech ATAI Life Sciences raising millions and earning the backing of prominent investors like Peter Thiel, but there’s a hole at the heart of the resurgence: Researchers still don’t fully understand how they work.

A new partnership between ATAI and world-renowned Mass General Hospital hopes to change that.